Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Open-Label, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT04539470 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT04539470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04539470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Open-Label, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 19, 2020
Completion date
February 24, 2023
Enrollment
18 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

acute graft-versus-host disease